Xcelience Launches New Service to Enhance Its Preformulation & Formulation Capabilities
The Tampa-based CRO continues its perpetual growth with new XRD support

Tampa, FL (May 6, 2008) – Xcelience, a leader in early drug development services, recently announced its expanded offering of X-ray Diffraction (XRD) capabilities to support clients’ needs in the areas of preformulation and formulation development.

“At the urging of several of our clients, we have committed to the purchase of an XRD instrument to enhance our overall capabilities in formulation analysis, polymorph identification, salt screen and selection, and crystallinity determination,” states Mark Cappucci, Team Leader for Preformulation and Formulation.

This information can be provided to aid early development activities with use of a small amount of sample which is nondestructive to the sample being evaluated. The XRD is the key technique for solid state drug analysis benefiting all stages of drug development, testing, production and stability. With the addition of the XRD, “Xcelience improves its scientific prowess for early drug development support.” states Derek Hennecke, President and CEO. “This new capability will help our clients make faster and smarter decisions on their New Chemical Entities and further enhance our scientific offerings to the science of drug development.”

Xcelience, LLC is an early development contract research organization focused on formulation development, preformulation services, analytical services and clinical trial manufacturing. The company has earned a solid reputation of accelerating early development activities to speed potential drugs to clinical trials while applying unparalleled scientific knowledge and experience.